Blood Biomarkers in Major Depression

NCT02209142 | Completed

• 1 other identifier: 2010-19
• Study Type: interventional
• Target: 275
• Locations: 1 country
• Sites: 1

Brief Summary

Depression is a leading cause of disability worldwide, affecting nearly 16% of the general population. Its physiopathology remains unclear. Based on gene-environment studies and epigenetic studies, a main hypothesis proposed that the major depressive episode (MDE) results from the convergence of multiple factors including biological factors such as multi-genic vulnerability, hormonal and immunological variations as well as environmental factors. As a consequence, mRNA could define a biological signature of the MDE.

Conditions

Major Depressive Disorder

Keywords

Major depression

Outcome Measures

Primary Outcomes (1)

• describe a transcriptional signature of the Major Depressive Episode.

  The major aim of our study is to compare the expression level of selected genes between patient suffering from major depression and control subjects and within patients across the MDE evolution. We plan to describe a transcriptional signature of the MDE.

  6 months

Secondary Outcomes (1)

• evaluate the role played by confounding factors as genetic polymorphisms,

  6 months

Other Outcomes (2)

• evaluate the role played by confounding factors as immune phenotype

  6 months

• evaluate the role played by confounding factors as psychotropic medications

  6 months

Study Arms (2)

pan-genomic screen

EXPERIMENTAL

A pan-genomic screen by blood prelevement and psychometric data collection will be set-up on a subset of MDE and control samples to identify mRNA candidates for a transcriptional signature of MDE,

Other: blood prelevement; Other: psychometric data collection

control

SHAM COMPARATOR

a pan genomic screening by blood prelevement and psychometric data collection wil be performed on healthy subject

Other: blood prelevement; Other: psychometric data collection

Interventions

blood prelevement OTHER

blood sample will be done at the inclusion then at T 2 weeks, T8 weeks, T30weeks

control; pan-genomic screen

psychometric data collection OTHER

Also known as: psychometric data collection wil be done ( hamilton scale and clinical exam)

control; pan-genomic screen

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Taken care by a grown-up psychiatric department, that the coverage(care) is realized in ambulatory or during a hospitalization

You may not qualify if:

• Schizophrenia

Sponsors & Collaborators

• Assistance Publique Hopitaux De Marseille: lead

Study Sites (1)

Assistance Publique Hopitaux de Marseille

Marseille, 13009, France

Location

Related Publications (1)

• Belzeaux R, Gorgievski V, Fiori LM, Lopez JP, Grenier J, Lin R, Nagy C, Ibrahim EC, Gascon E, Courtet P, Richard-Devantoy S, Berlim M, Chachamovich E, Theroux JF, Dumas S, Giros B, Rotzinger S, Soares CN, Foster JA, Mechawar N, Tall GG, Tzavara ET, Kennedy SH, Turecki G. GPR56/ADGRG1 is associated with response to antidepressant treatment. Nat Commun. 2020 Apr 2;11(1):1635. doi: 10.1038/s41467-020-15423-5.

  PMID: 32242018 DERIVED

MeSH Terms

Conditions

Depressive Disorder, Major

Condition Hierarchy (Ancestors)

Depressive Disorder; Mood Disorders; Mental Disorders

Study Officials

• jean Naudin, MD

  Assistance Publique Hopitaux De Marseille

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 4, 2014
• First Posted: August 5, 2014
• Study Start: February 22, 2012
• Primary Completion: November 10, 2022
• Study Completion: November 10, 2022
• Last Updated: April 21, 2023

Record last verified: 2023-04

Locations

FR (1)